Cancer-associated thrombosis in hematologic malignancies
This article summarizes the current understanding, risk factors, prediction models, and optimal prevention and treatment strategies of CAT in hematologic malignancies on a disease-by-disease basis, including acute leukemia, lymphoma, myeloma, and myeloproliferative neoplasms. Specific considerations of novel molecular targeted therapeutics introduced in recent years, such as immunomodulatory drugs and tyrosine kinase inhibitors, are also discussed based on the latest clinical trials.PMID:38270784 | DOI:10.1007/s12185-023-03690-z
Source: International Journal of Hematology - Category: Hematology Authors: Masahiko Fukatsu Takayuki Ikezoe Source Type: research
More News: Acute Leukemia | Bleeding | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma | Myeloproliferative Disorders | Thrombocytopenia | Thrombosis